Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis

Journal of Clinical Pathology

Volumn 62, Issue 8, 2009, Pages 690-693

  Schmitz, K J ^a   Wohlschlaeger, J ^a   Lang, H ^a   Sotiropoulos, G C ^a   Kaiser, G M ^a   Schmid, K W ^a   Baba, H A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLOOXYGENASE 2; EPIDEMIOLOGIC METHODS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68149178686     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.065888     Document Type: Article

References (23)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917
2. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750 (Pubitemid 29114292)
3. Khuder SA, Herial NA, Mutgi AB, et al. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005;127:748-754 (Pubitemid 40775501)
4. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114. (Pubitemid 32641352)
5. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569 (Pubitemid 37411436)
6. Leng J, Han C, Demetris AJ, et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxibinduced apoptosis. Hepatology 2003;38:756-768 (Pubitemid 37052162)
7. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxibinduced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005;11:8213-8221
8. Kern MA, Schoneweiss MM, Sahi D, et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004;25:1193-1199 (Pubitemid 38968047)
9. Kern MA, Haugg AM, Koch AF, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006;66:7059-7066
10. Breinig M, Rieker R, Eiteneuer E, et al. Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer 2008;122:547-557 (Pubitemid 350308945)
11. Sobin LH, Wittekind C. International Union against Cancer. TNM Classification of Malignant Tumours. 6 edn. New York: Wiley-Liss, 2002.
12. Schmitz KJ, Lang H, Wohlschlaeger J, et al. Elevated expression of cyclooxygenase- 2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 2007;450:135-141 (Pubitemid 46295237)
13. Qiu DK, Ma X, Peng YS, et al. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002;8:815-817
14. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-696 (Pubitemid 29109581)
15. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-894
16. Morinaga S, Tarao K, Yamamoto Y, et al. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1249-1255 (Pubitemid 47222643)
17. Foster J, Black J, Levea C, et al. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol 2007;14:752-758 (Pubitemid 46175323)
18. Schmidt CM, Wang Y, Wiesenauer C. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. J Gastrointest Surg 2003;7:1024-1033 (Pubitemid 37524070)
19. Pearson G, Robinson F, Beers GT, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183 (Pubitemid 32458157)
20. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186
21. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-2444
22. Cusimano A, Fodera D, D'Alessandro N, et al. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther 2007;6:1461-1468 (Pubitemid 351590359)
23. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48:83-90. (Pubitemid 350191996)